A rapid and sensitive LC-MS/MS method for determination of fluconazole in human plasma and its application in infants with candida infections

Therapeutic Drug Monitoring

Volumn 31, Issue 6, 2009, Pages 703-709

  Wu, Di ^a   Wade, Kelly C ^a,b   Paul, Dustin J ^a,b   Barrett, Jeffrey S ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Fluconazole; High performance liquid chromatographytandem mass spectrometry (LC MS MS); Infant; Pharmacokinetics; Therapeutic drug monitoring

Indexed keywords

DEUTERIUM; FLUCONAZOLE;

ACCURACY; ARTICLE; CANDIDIASIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MONITORING; DRUG STABILITY; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; INFANT; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; ROOM TEMPERATURE; TANDEM MASS SPECTROMETRY; VALIDATION STUDY;

ANALYTIC SAMPLE PREPARATION METHODS; ANTIFUNGAL AGENTS; CALIBRATION; CANDIDIASIS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; FLUCONAZOLE; HUMANS; INFANT; INFANT, NEWBORN; LIMIT OF DETECTION; MICROCHEMISTRY; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY; TIME FACTORS;

EID: 73849150688     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181b20b40     Document Type: Article

References (53)

1. Kaufman DA. Fluconazole prophylaxis: Can we eliminate invasive Candida infections in the neonatal ICU? Curr Opin Pediatr. 2008;20: 332-340.
2. Marodi L, Johnston RB Jr. Invasive Candida species disease in infants and children: Occurrence, risk factors, management, and innate host defense mechanisms. Curr Opin Pediatr. 2007;19:693-697.
3. Zaoutis T, Walsh TJ. Antifungal therapy for neonatal candidiasis. Curr Opin Infect Dis. 2007;20:592-597.
4. Zaoutis TE, Heydon K, Localio R, et al. Outcomes attributable to neonatal candidiasis. Clin Infect Dis. 2007;44:1187-1193.
5. Benjamin DK Jr, Stoll BJ, Fanaroff AA, et al. Neonatal candidiasis among extremely low birth weight infants: Risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics. 2006;117: 84-92.
6. Diflucan®. Food and Drug Administration, United States Department of Health and Human Services. June 27, 2006. Available at: http://www.fda.gov/ medwatch/SAFETY/2004/oct-PI/Diflucan-PI.pdf. Accessed January 26, 2009.
7. Almirante B, Rodriguez D. Antifungal agents in neonates: Issues and recommendations. Paediatr Drugs. 2007;9:311-321.
8. Burwell LA, Kaufman D, Blakely J, et al. Antifungal prophylaxis to prevent neonatal candidiasis: A survey of perinatal physician practices. Pediatrics. 2006;118:e1019-e1026.
9. Carey AJ, Saiman L, Polin RA. Hospital-acquired infections in the NICU: Epidemiology for the new millennium. Clin Perinatol. 2008;35:223-249.
10. Curtis C, Shetty N. Recent trends and prevention of infection in the neonatal intensive care unit. Curr Opin Infect Dis. 2008;21:350-356.
11. Healy CM, Campbell JR, Zaccaria E, et al. Fluconazole prophylaxis in extremely low birth weight neonates reduces invasive candidiasis mortality rates without emergence of fluconazole-resistant Candida species. Pediatrics. 2008;121:703-710.
12. Manzoni P, Stolfi I, Pugni L, et al. A multicenter, randomized trial of prophylactic fluconazole in preterm neonates. N Engl J Med. 2007;356: 2483-2495.
13. Steinbach WJ. Antifungal agents in children. Pediatr Clin North Am. 2005;52:895-915.
14. Pfaller MA, Diekema DJ, Sheehan DJ. Interpretive breakpoints for fluconazole and Candida revisited: A blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev. 2006;19:435-447.
15. Pai MP, Turpin RS, Garey KW. Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia. Antimicrob Agents Chemother. 2007;51:35-39.
16. Baddley JW, Patel M, Bhavnani SM, et al. Association of fluconazole pharmacodynamics with mortality in patients with candidemia. Antimicrob Agents Chemother. 2008;52:3022-3028.
17. Rodriguez-Tudela JL, Almirante B, Rodriguez-Pardo D, et al. Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia. Antimicrob Agents Chemother. 2007;51:3599-3604.
18. Wade KC, Wu D, Kaufman DA, et al. Population pharmacokinetics of fluconazole in young infants. Antimicrob Agents Chemother. 2008;52: 4043-4049.
19. Capparelli EV, Williams PJ. Pharmacometrics in pharmacotherapy and drug development: Pediatric application. In: Ette EI, Williams PJ, eds. Pharmacometrics: The Science of Quantitative Pharmacology. Hoboken, NJ: John Wiley & Sons, 2007:955-975.
20. Cociglio M, Brandissou S, Alric R, et al. High-performance liquid chromatographic determination of fluconazole in plasma. J Chromatogr B Biomed Appl. 1996;686:11-17.
21. Egle H, Trittler R, Kummerer K. A new, rapid, fully automated method for determination of fluconazole in serum by column-switching liquid chromatography. Ther Drug Monit. 2004;26:425-431.
22. Inagaki K, Takagi J, Lor E, et al. Determination of fluconazole in human serum by solid-phase extraction and reversed-phase high-performance liquid chromatography. Ther Drug Monit. 1992;14:306-311.
23. Kim SS, Im HT, Kang IM, et al. An optimized analytical method of fluconazole in human plasma by high-performance liquid chromatog-raphy with ultraviolet detection and its application to a bioequivalence study. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;852: 174-179.
24. Koks CH, Rosing H, Meenhorst PL, et al. High-performance liquid chromatographic determination of the antifungal drug fluconazole in plasma and saliva of human immunodeficiency virus-infected patients. J Chromatogr B Biomed Appl. 1995;663:345-351.
25. Lazo de la Vega S, Volkow P, Yeates RA, et al. Administration of the antimycotic agents fluconazole and itraconazole to leukaemia patients: A comparative pharmacokinetic study. Drugs Exp Clin Res. 1994;20:69-75.
26. Marchetti O, Majcherczyk PA, Glauser MP, et al. Sensitive bioassay for determination of fluconazole concentrations in plasma using a Candida albicans mutant hypersusceptible to azoles. Antimicrob Agents Chemo-ther. 2001;45:696-700.
27. Moraes LA, Lerner FE, Moraes ME, et al. Fluconazole bioequivalence study: quantification by tandem mass spectrometry. Ther Drug Monit. 1999;21:200-207.
28. Pereira R, Fidelis S, Vanunci ML, et al. Bioequivalence study of two fluconazole capsule formulations in healthy volunteers. Int J Clin Pharmacol Ther. 2004;42:39-42.
29. Ribeiro W, Zappi EA, Moraes ME, et al. Comparative bioavailability of two fluconazole capsule formulations in healthy volunteers. Arzneimit-telforschung. 2000;50:1028-1032.
30. Zhang S, Mada SR, Torch M, et al. Development and validation of a high-performance liquid chromatographic assay for the determination of fluconazole in human whole blood using solid phase extraction. Ther Drug Monit. 2008;30:314-319.
31. Guidance for Industry: Bioanalytical Method Validation. Food and Drug Administration, United States Department of Health and Human Services. May 2001. Available at: http://www.fda.gov/cder/guidance/4252fnl.pdf. Accessed January 26, 2009.
32. Matuszewski BK. Standard line slopes as a measure of a relative matrix effect in quantitative HPLC-MS bioanalysis. J Chromatogr B Analyt Technol Biomed Life Sci. 2006;830:293-300.
33. Van Eeckhaut A, Lanckmans K, Sarre S, et al. Validation of bioanalytical LC-MS/MS assays: Evaluation of matrix effects. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877:2198-2207.
34. Chambers E, Wagrowski-Diehl DM, Lu Z, et al. Systematic and comprehensive strategy for reducing matrix effects in LC/MS/MS analyses. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;852: 22-34.
35. Lindegardh N, Annerberg A, White NJ, et al. Development and validation of a liquid chromatographic-tandem mass spectrometric method for determination of piperaquine in plasma stable isotope labeled internal standard does not always compensate for matrix effects. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;862:227-236.
36. Shin J, Pauly DF, Johnson JA, et al. Simplified method for determination of clarithromycin in human plasma using protein precipitation in a 96-well format and liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;871:130-134.
37. Stokvis E, Rosing H, Beijnen JH. Stable isotopically labeled internal standards in quantitative bioanalysis using liquid chromatography/mass spectrometry: Necessity or not? Rapid Commun Mass Spectrom. 2005;19: 401-407.
38. Taylor PJ. Matrix effects: The Achilles heel of quantitative high-performance liquid chromatography-electrospray-tandem mass spectrom-etry. Clin Biochem. 2005;38:328-334.
39. Wang S, Cyronak M, Yang E. Does a stable isotopically labeled internal standard always correct analyte response? A matrix effect study on a LC/ MS/MS method for the determination of carvedilol enantiomers in human plasma. J Pharm Biomed Anal. 2007;43:701-707.
40. Xu RN, Fan L, Rieser MJ, et al. Recent advances in high-throughput quantitative bioanalysis by LC-MS/MS. J Pharm Biomed Anal. 2007;44: 342-355.
41. Smith J, Andes D. Therapeutic drug monitoring of antifungals: Pharmacokinetic and pharmacodynamic considerations. Ther Drug Monit. 2008;30:167-172.
42. Summers KK, Hardin TC, Gore SJ, et al. Therapeutic drug monitoring of systemic antifungal therapy. J Antimicrob Chemother. 1997;40:753-764.
43. Hope WW, Billaud EM, Lestner J, et al. Therapeutic drug monitoring for triazoles. Curr Opin Infect Dis. 2008;21:580-586.
44. Cha R, Sobel JD. Fluconazole for the treatment of candidiasis: 15 years experience. Expert Rev Anti Infect Ther. 2004;2:357-366.
45. Charlier C, Hart E, Lefort A, et al. Fluconazole for the management of invasive candidiasis: Where do we stand after 15 years? J Antimicrob Chemother. 2006;57:384-410.
46. Pittrow L, Penk A. Plasma and tissue concentrations of fluconazole and their correlation to breakpoints. Mycoses. 1997;40:25-32.
47. Modi N. Clinical implications of postnatal alterations in body water distribution. Semin Neonatol. 2003;8:301-306.
48. Debruyne D, Ryckelynck JP. Clinical pharmacokinetics of fluconazole. Clin Pharmacokinet. 1993;24:10-27.
49. Humphrey MJ, Jevons S, Tarbit MH. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrob Agents Chemother. 1985;28:648-653.
50. Neville KA, Blake MJ, Reed MD, et al. Pediatric pharmacology. In: Waldman SA, Terzic A, eds. Pharmacology and Therapeutics: Principles to Practice. Philadelphia: Saunders, Elsevier, 2008:239-249.
51. Schwarze R, Penk A, Pittrow L. Administration of fluconazole in children below 1 year of age. Mycoses. 1999;42:3-16.
52. Playford EG, Sorrell TC. Optimizing therapy for Candida infections. Semin Respir Crit Care Med. 2007;28:678-688.
53. Gorodischer N. Therapeutic drug monitoring In: Jacqz-Aigrain E, Choonara I, eds. Paediatric Clinical Pharmacology. New York: Taylor & Francis Group, 2006:177-189.